drugset / Trial / NCT04597437
Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)
Phase 2
Recruiting
74 enrolled
George Washington University
Clinica de la Costa · collabGlobal Disease Research · collabNaval Medical Research Center · collabUniversidad Libre de Barranquilla · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever.
Timeline
- Start
- 2024-03-15
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zanamivir | Small molecule | 12 mg/kg | Intravenous |
| Subject | Zanamivir | Small molecule | 600 mg | Intravenous |